PDF herunterladen
Digestive Disease Interventions 2022; 06(01): 003-012
DOI: 10.1055/s-0041-1741520
Review Article

State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies

Mohamed Tantawi 
1   Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
,
Susan Shamimi-Noori
2   Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania
,
Colette M. Shaw
1   Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
,
John R. Eisenbrey
1   Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Locoregional therapies (LRTs) are an essential management tool in the treatment of primary liver cancers or metastatic liver disease. LRTs include curative and palliative modalities. Monitoring treatment response of LRTs is crucial for maximizing benefit and improving clinical outcomes. Clinical use of contrast-enhanced ultrasound (CEUS) was introduced more than two decades ago. Its portability, cost effectiveness, lack of contraindications and safety make it an ideal tool for treatment monitoring in numerous situations. Two-dimensional dynamic CEUS has been proved to be equivalent to the current imaging standard in the guidance of LRTs, assessment of their adequacy, and detection of early tumor recurrence. Recent technical advances in ultrasound transducers and image processing have made 3D CEUS scanning widely available on most commercial ultrasound systems. 3D scanning offers a broad multiplanar view of anatomic structures, overcoming many limitations of two-dimensional scanning. Furthermore, many ultrasound systems provide real-time dynamic 3D CEUS, also known as 4D CEUS. Volumetric CEUS has shown to perform better than 2D CEUS in the assessment and monitoring of some LRTs. CEUS presents a valid alternative to the current imaging standards with reduced cost and decreased risk of complications. Future efforts will be directed toward refining the utility of 4D CEUS through approaches such as multi-parametric quantitative analysis and machine learning algorithms.

Keywords

contrast-enhanced ultrasound - 4D - volumetric imaging - hepatocellular carcinoma - locoregional therapy - treatment response assessment


Publikationsverlauf

Eingereicht: 25. April 2021

Angenommen: 09. November 2021

Artikel online veröffentlicht:
11. Januar 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019; 25 (32) 4614-4628
    CrossrefPubMedSuche in Google Scholar
  • 2 Yang Y, Chen Y, Zhang X. et al. Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. Eur J Radiol 2021; 138: 109623
    CrossrefPubMedSuche in Google Scholar
  • 3 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (01) 52-60
    Thieme ConnectPubMedSuche in Google Scholar
  • 4 LI-RADS® ACoRCo. CT/MRI LI-RADS® v2018 CORE. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf . Accessed 23 March 2021. Published 2018
    PubMedSuche in Google Scholar
  • 5 Gummadi S, Eisenbrey JR, Lyshchik A. Contrast-enhanced ultrasonography in interventional oncology. Abdom Radiol (NY) 2018; 43 (11) 3166-3175
    CrossrefPubMedSuche in Google Scholar
  • 6 Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY) 2021; 46 (08) 3579-3595
    CrossrefPubMedSuche in Google Scholar
  • 7 LI-RADS® ACoRCo. CEUS LI-RADS® v2017 CORE. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf . Accessed 23 March, 2021. Published 2017
    PubMedSuche in Google Scholar
  • 8 Kielar A, Fowler KJ, Lewis S. et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018; 43 (01) 218-230
    CrossrefPubMedSuche in Google Scholar
  • 9 Lyshchick A. Specialty Imaging: Fundamentals of CEUS E-Book. Elsevier Health Sciences; 2019
    Suche in Google Scholar
  • 10 Fenster A, Parraga G, Bax J. Three-dimensional ultrasound scanning. Interface Focus 2011; 1 (04) 503-519
    CrossrefPubMedSuche in Google Scholar
  • 11 Dietrich CF, Nolsøe CP, Barr RG. et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med 2020; 41 (05) 562-585
    Thieme ConnectPubMedSuche in Google Scholar
  • 12 Durot I, Wilson SR, Willmann JK. Contrast-enhanced ultrasound of malignant liver lesions. Abdom Radiol (NY) 2018; 43 (04) 819-847
    CrossrefPubMedSuche in Google Scholar
  • 13 Chiorean L, Tana C, Braden B. et al. Advantages and Limitations of Focal Liver Lesion Assessment with Ultrasound Contrast Agents: Comments on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Guidelines. Med Princ Pract 2016; 25 (05) 399-407
    CrossrefPubMedSuche in Google Scholar
  • 14 Dietrich CF, Averkiou MA, Correas JM, Lassau N, Leen E, Piscaglia F. An EFSUMB introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for quantification of tumour perfusion. Ultraschall Med 2012; 33 (04) 344-351
    Thieme ConnectPubMedSuche in Google Scholar
  • 15 Sidhu PS, Cantisani V, Dietrich CF. et al. The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). Ultraschall Med 2018; 39 (02) e2-e44
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Wilson SR, Lyshchik A, Piscaglia F. et al. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol (NY) 2018; 43 (01) 127-142
    CrossrefPubMedSuche in Google Scholar
  • 17 Du J, Li HL, Zhai B, Chang S, Li FH. Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results. Ultrasound Med Biol 2015; 41 (09) 2400-2411
    CrossrefPubMedSuche in Google Scholar
  • 18 Moschouris H, Malagari K, Dimakis A, Kiakidis T, Anagnostopoulou A. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography. Cardiovasc Intervent Radiol 2020; 43 (07) 1075-1083
    CrossrefPubMedSuche in Google Scholar
  • 19 Llovet JM, Kelley RK, Villanueva A. et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7 (01) 6
    Suche in Google Scholar
  • 20 Liu Z, Wang X, Xing L, Pan Y, Huang S. The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma. Cancer Biother Radiopharm 2019; 34 (10) 621-625
    CrossrefPubMedSuche in Google Scholar
  • 21 Mauri G, Porazzi E, Cova L. et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment. Insights Imaging 2014; 5 (02) 209-216
    CrossrefPubMedSuche in Google Scholar
  • 22 Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol 2011; 17 (45) 4952-4959
    CrossrefPubMedSuche in Google Scholar
  • 23 Chen MH, Yang W, Yan K. et al. Large liver tumors: protocol for radiofrequency ablation and its clinical application in 110 patients–mathematic model, overlapping mode, and electrode placement process. Radiology 2004; 232 (01) 260-271
    CrossrefPubMedSuche in Google Scholar
  • 24 Meloni MF, Andreano A, Zimbaro F, Lava M, Lazzaroni S, Sironi S. Contrast enhanced ultrasound: Roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumors. J Ultrasound 2012; 15 (04) 207-214
    CrossrefPubMedSuche in Google Scholar
  • 25 Francica G, Meloni MF, Riccardi L. et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. Eur J Radiol 2018; 105: 96-101
    CrossrefPubMedSuche in Google Scholar
  • 26 Roccarina D, Garcovich M, Ainora ME. et al. Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World J Hepatol 2015; 7 (14) 1866-1874
    CrossrefPubMedSuche in Google Scholar
  • 27 Vilana R, Bianchi L, Varela M. et al; BCLC Group. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. Eur Radiol 2006; 16 (11) 2454-2462
    CrossrefPubMedSuche in Google Scholar
  • 28 Yan FH, Zhou KR, Cheng JM. et al. Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE. World J Gastroenterol 2002; 8 (04) 658-662
    CrossrefPubMedSuche in Google Scholar
  • 29 Zhong J, Su Z, Zhang Y. et al. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis. J Ultrasound Med 2018; 37 (08) 1881-1890
    CrossrefPubMedSuche in Google Scholar
  • 30 Tantawi M, Liu J-B, Eisenbrey JR. Recent advances in microbubble-augmented cancer therapy. Adv Ultrasound Diagn Therap 2020; 04 (03) 155-168
    CrossrefPubMedSuche in Google Scholar
  • 31 Shaw CM, Eisenbrey JR, Lyshchik A. et al. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med 2015; 34 (05) 859-867
    CrossrefPubMedSuche in Google Scholar
  • 32 Wessner CE, Shaw CM, Stanczak M. et al. Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity. Ultrasound Q 2020; 36 (03) 218-223
    CrossrefPubMedSuche in Google Scholar
  • 33 Liu D, Liu F, Xie X. et al. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol 2020; 30 (04) 2365-2376
    CrossrefPubMedSuche in Google Scholar
  • 34 Oezdemir I, Wessner CE, Shaw C, Eisenbrey JR, Hoyt K. Tumor Vascular Networks Depicted in Contrast-Enhanced Ultrasound Images as a Predictor for Transarterial Chemoembolization Treatment Response. Ultrasound Med Biol 2020; 46 (09) 2276-2286
    CrossrefPubMedSuche in Google Scholar
  • 35 Andreana L, Isgrò G, Marelli L. et al. Treatment of hepatocellular carcinoma (HCC) by intra-arterial infusion of radio-emitter compounds: trans-arterial radio-embolisation of HCC. Cancer Treat Rev 2012; 38 (06) 641-649
    CrossrefPubMedSuche in Google Scholar
  • 36 Venkatanarasimha N, Gogna A, Tong KTA. et al. Radioembolisation of hepatocellular carcinoma: a primer. Clin Radiol 2017; 72 (12) 1002-1013
    CrossrefPubMedSuche in Google Scholar
  • 37 Eisenbrey JR, Forsberg F, Wessner CE. et al. US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial. Radiology 2021; 298 (02) 450-457
    CrossrefPubMedSuche in Google Scholar
  • 38 Tantawi M, Delaney LJ, Forsberg F. et al. Long-term HCC response to radioembolization can be predicted within two weeks post-treatment with contrast-enhanced ultrasound. RSNA Annual Meeting; 2020
    PubMedSuche in Google Scholar
  • 39 Kaplan E, Kaplan S. Computed tomographic perfusion imaging for the prediction of response transarterial radioembolization with Yttrium‑90 glass microspheres of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2021; 25 (01) 366-375
    PubMedSuche in Google Scholar
  • 40 Downey DB, Fenster A, Williams JC. Clinical utility of three-dimensional US. Radiographics 2000; 20 (02) 559-571
    CrossrefPubMedSuche in Google Scholar
  • 41 Nelson TR, Pretorius DH. Three-dimensional ultrasound imaging. Ultrasound Med Biol 1998; 24 (09) 1243-1270
    CrossrefPubMedSuche in Google Scholar
  • 42 Xu HX, Lu MD, Xie XH. et al. Three-dimensional contrast-enhanced ultrasound of the liver: experience of 92 cases. Ultrasonics 2009; 49 (03) 377-385
    CrossrefPubMedSuche in Google Scholar
  • 43 Helck A, D'Anastasi M, Notohamiprodjo M, Thieme S, Reiser M, Clevert DA. Improved visualization of renal lesions using three-dimensional ultrasound–a feasibility study. Clin Hemorheol Microcirc 2011; 49 (1-4): 537-550
    CrossrefPubMedSuche in Google Scholar
  • 44 Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA. et al. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001; 40 (03) 285-293
    CrossrefPubMedSuche in Google Scholar
  • 45 Sridharan A, Eisenbrey JR, Machado P. et al. Quantitative analysis of vascular heterogeneity in breast lesions using contrast-enhanced 3-D harmonic and subharmonic ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2015; 62 (03) 502-510
    CrossrefPubMedSuche in Google Scholar
  • 46 Luo W, Numata K, Morimoto M. et al. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology 2009; 251 (01) 287-295
    CrossrefPubMedSuche in Google Scholar
  • 47 Calio BP, Lyshchik A, Li J. et al. Long Term Surveillance of Renal Cell Carcinoma Recurrence Following Ablation using 2D and 3D Contrast-Enhanced Ultrasound. Urology 2018; 121: 189-196
    CrossrefPubMedSuche in Google Scholar
  • 48 El Kaffas A, Sigrist RMS, Fisher G. et al. Quantitative Three-Dimensional Dynamic Contrast-Enhanced Ultrasound Imaging: First-In-Human Pilot Study in Patients with Liver Metastases. Theranostics 2017; 7 (15) 3745-3758
    CrossrefPubMedSuche in Google Scholar
  • 49 El Kaffas A, Hoogi A, Zhou J. et al. Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response. Sci Rep 2020; 10 (01) 6996
    CrossrefPubMedSuche in Google Scholar
  • 50 Xu EJ, Lv SM, Li K. et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia 2018; 34 (06) 870-876
    CrossrefPubMedSuche in Google Scholar
  • 51 Xu HX, Lu MD, Xie XH. et al. Treatment response evaluation with three-dimensional contrast-enhanced ultrasound for liver cancer after local therapies. Eur J Radiol 2010; 76 (01) 81-88
    CrossrefPubMedSuche in Google Scholar
  • 52 Numata K, Fukuda H, Ohto M. et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. Eur J Radiol 2010; 75 (02) e67-e75
    CrossrefPubMedSuche in Google Scholar
  • 53 Luo W, Numata K, Morimoto M. et al. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol 2010; 75 (01) 91-97
    CrossrefPubMedSuche in Google Scholar
  • 54 Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R. 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med (Torino) 2015; 120 (08) 695-704
    CrossrefPubMedSuche in Google Scholar
  • 55 Leen E, Kumar S, Khan SA. et al. Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gastroenterol 2009; 15 (03) 289-299
    CrossrefPubMedSuche in Google Scholar
  • 56 Dong FJ, Xu JF, Du D. et al. 3D analysis is superior to 2D analysis for contrast-enhanced ultrasound in revealing vascularity in focal liver lesions - A retrospective analysis of 83 cases. Ultrasonics 2016; 70: 221-226
    CrossrefPubMedSuche in Google Scholar
  • 57 Wang Y, Jing X, Ding J. Clinical value of dynamic 3-dimensional contrast-enhanced ultrasound imaging for the assessment of hepatocellular carcinoma ablation. Clin Imaging 2016; 40 (03) 402-406
    CrossrefPubMedSuche in Google Scholar
  • 58 Cao J, Dong Y, Mao F, Wang W. Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. BioMed Res Int 2018; 2018: 6469703
    PubMedSuche in Google Scholar
  • 59 Nam K, Stanczak M, Lyshchik A. et al. Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed Phys Eng Express 2018; 4 (03) 035039-035039
    CrossrefPubMedSuche in Google Scholar
  • 60 Wildeboer RR, Postema AW, Demi L, Kuenen MPJ, Wijkstra H, Mischi M. Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer. Eur Radiol 2017; 27 (08) 3226-3234
    CrossrefPubMedSuche in Google Scholar